echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Somaglutide combined cilofexo/firsocostat treatment NASH II with positive results

    Somaglutide combined cilofexo/firsocostat treatment NASH II with positive results

    • Last Update: 2021-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 15th Gilead/Noor and Nord jointly published the results of the Phase II proof-of-concept study.
    the 5-arm, 24-week phase II clinical study, which included 108 subjects, evaluated noro and Nord's glutatrogin-like peptide-1 (GLP-1) subject agonist Somalutide in combination with Gilead The efficacy and safety of the steroid faniol X-subject (FXR) astigtor cilofexo and or Gilead acetyl coenzyme A carbohydrase (ACC) inhibitor firsocostat for the treatment of non-alcoholic fatty hepatitis (NASH).
    results were presented at the 71st Annual Meeting/Virtual Meeting of the American Association for the Study of Hepatology (AASLD).
    the study reached its main clinical endpoint, NASH patients with mild and moderate hepatic fibrosis were well-resistant to all treatment options.
    most common adverse events (AEs) are gastrointestinal reactions.
    itching symptoms in patients in the cilofexor group.
    all groups had between 5% and 14% of patients who stopped taking drugs because of AEs. After 24 weeks of
    treatment, an ex post-mortem analysis of the exploratory therapeutic endpoint of the evaluation of biomarkers of liver health showed a statistically significant improvement in the liver fat degeneration (measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver injury (serum alanine amino transferase (ALT)) indicators compared to the somalutide monotherapy group.
    Cilofexo is a nonsteroidal funiol X-subject (FXR) exciter developed jointly by Gilead and Phenex Pharma, and the adaptations currently being developed are as follows: Source: Pharma GoFirsocostat, a acetyl coenzyme A carbidease (ACC) inhibitor developed jointly by Gilead and Nimbus Therapeutics. ACC is the speed limit enzyme in fat synthesis process from the beginning, NASH patients with significantly faster body fat rebirth, so ACC inhibitors can reduce lipid synthesis or accelerate its decomposition.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.